MGMT and glioblastoma: While lomustine chemotherapy remains the standard treatment for most patients, response is limited in MGMT non-methylated tumors.<h4>Research question</h4>Does maximal surgical resection improve survival outcomes in recurrent glioblastoma patients with poor response to systemic therapy?<h4>Material and methods</h4>We performed a retrospective analysis of rGB patients who underwent re-resection between January 2016 and December 2021.